The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Zak Mir tips them to go to 32p, of course they could easily go a lot higher depending on trial results:
https://www.proactiveinvestors.co.uk/companies/news/306955/allergy-therapeutics-shares-tipped-to-rise-to-32p-6955.html
ABBOT LABORATORIES is a all around the world mkt capt over 200 billion net profit over 7 billion over 100000 staff -- now this is the good bit they are the top share holder here 240 million shares , ASK yourself why i tell because this is so undervalued , The giant pharma group gsk are also shareholder as well .This has made my day
OFFERING 21.75 SELL 22 top up some more as i can see a re rate coming . IM done now will look in from time to time these are lomg term
Thanks paul fg agy is a under valued company if i ever seen one .IT be a slower burner but i see its ready to bounce . I have the research notes and very impressed .I bought my first lot today .and will carry on . IF they can get things right 20p will be history .Happy to relax with this share as i can see ita slower one .NOT many companys with millions of pounds in cash =9 PERCENT growth every year last 22 years .That takes some doing .ALL road map out to go presence in most of europe .Looking at other markets . Happy im in gla
Indeed there's a lot going for AGY and this year there's the potential for a number of exciting announcements.
ON the trading front - the bid / offer can be sensitive to the slightest trading activity at times but the price seems to have found a pretty solid floor around 20p it it has been hit by several 50k chinks without moving, so current sensitivity is on the offer. When it's like this to get trade you generally have to hit the offer, with the hope that is might trade better, to get done.
There does seem to be upward bias at the moment, though you never know...
Goodluck & welcome.
Share price has not done a lot for the progress they have made .. WELL hopefully i can get my nice order at 21 accepted today sometime . I HAVE a feeling agy is about to turn ormally right so will try a token order to get foot in the door as well
Very impressed with cash postion etc .. Future plans for q 3 usa breaking into other mkts . KICKING myself could of bought yesterday at 20,8 but didnt ,However today up the spread here is spitefull buying a lot at once it will hurt me . Any reason why director pledge share reminds of pawning on tv
We've seen in recent days the hazards of shareholders' margin calls being triggered (Archegos etc) and what concerns me with AGY is we're seeing the CEO borrowing against his holding in the company and the then probability of his margin call forcing him to sell his equity should the SP take a sudden and deep downward swing, follow that up with the subsequent RNS that the CEO is selling stock.
Of course you could argue the opposite that his putting up his equity stake as collateral demonstrates both his and his lenders (Santander I think) confidence in the share.
But I would rather not have seen him borrowing against his holdings in case of any market manipulations....
nice to see we settled on a multi-year high.
Thanks - that was really helpful.
For me it was really only this: https://www.lse.co.uk/rns/AGY/top-line-phase-iii-results-from-b301-trial-hjzdp6rcqmu1bgi.html
I know they then won costs and an invalidation of the trial BUT what was more worrying for me is that they should have been all over this beforehand. It has set us back.
I've been investing in in biotechs for many years and I'm used to the CFO obviously getting headline space BUT I'm also used to a lot more emphasis being placed on the science. With AGY presentations we get a lot from the Finance and Communications departments but really what investors want to hear about is the science. I was a little concerned at the last Q&A, where one of the analysts asked about the differences between the Peanut treatment already on the market and the one AGY are developing - this wasn't adequately answered on the call and I think it should have been.
I would prefer them to assign equal value to the medical aspects as they do accountancy during these presentations and to have an expert there to address these issues.
Many may feel they do already but it is just my opinion.
What I like about AGY is that it isn't only about the pipeline like many small biotechs, but already has excellent ground-breaking products in the marketplace generating increasing revenues to fund its pipeline.
Can I ask what you think the stumbling blocks have been?
Agreed.
What I like about this company is that everything it's doing is going to improve peoples quality of life and if it gets it right there is huge potential.
Admittedly, as has been pointed out, there have been stumbles along the way, but such is the nature with these companies and hopefully lessons learned.
That would be good. I bought in here because of peanut allergy in my family. I Thought the murine model data was very promising, then everything else on top of it + cash in the bank. Immunobon v interesting too. There are millions of people who would love to address the cause of their problems - a poor immune system, rather than take anti histamines. I bought in at the wrong time - August - but have been wondering why the market has overlooked this potential gem. Perhaps they have woken up?
I think we can assume there's been a positive reaction at the conference - maybe the company is finally getting noticed.
So, Immunobon is a supplement containing whey and vitamins. A product that is not classified as pharmaceutical nor has scientific relevance. Another supplement in a pretty saturated market, that will try to compete against established supplement brands with better marketing, distribution, research etc. in the field. This product is the result of years of R&D and a fully fledged marketing team? Seriously? A commercial and reputational disaster waiting to happen. This is only tarnishing even further investors opinions on AGY, no wonder why after each RNS there are a few hours of excitement and then the share inexorably drops. They are continuously failing to impress and regain investors trust, a few years ago they were speaking about registering their vaccines, developing a peanut vaccine, entering the US market… now we’re talking supplements. In the meantime competitors successfully managed to register their products in key markets. A company with no vision or direction, one failure after the other…Buyers beware.
Link to transcript of the presentation made to analysts, note the q&a at the end, it really does reinforce my suspicion that the market has overlooked just how big immunoBon could be.
https://finance-yahoo-com.cdn.ampproject.org/v/s/finance.yahoo.com/amphtml/news/edited-transcript-agy-l-earnings-093000504.html?amp_js_v=a6&_gsa=1&usqp=mq331AQHKAFQArABIA%3D%3D#aoh=16148983410632&referrer=https%3A%2F%2Fwww.google.com&_tf=From%20%251%24s&share=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fedited-transcript-agy-l-earnings-093000504.html
Here's a video update for todays results from CEO Manuel Llobet & Nick Wykeman:
https://youtu.be/rLstRArTJu0
Interesting to hear here that they plan significant investment into the immunoBon marketing/launch in Germany, I really think this product could add significantly to the bottom line going forward so I hope they provide more detailed analysis in future updates.
So our cash balance is around £48m, and the current market cap is around £120m
I know we'll eat into a good part of the cash balance this year with various trials but we also have an impressively increasing revenue stream.
Seriously undervalued.
Interesting summary of state of company as of now given to JP Morgan Conference here: https://www.allergytherapeutics.com/investors/results-reports-and-presentations/
with reference to ImmunoBon read slide 10.
This is the link to the webcast for the financial results tomorrow morning at 9:30 a.m.
https://www.lsegissuerservices.com/spark/AllergyTherapeutics/events/27be0274-2be7-4f4d-912d-5ab92e872ea4
Price action today looks promising for results RNS tomorrow
Interestingly, this analysis places a valuation of 51p per share given cash balance, revenues, and current pipeline progress.
https://www.trinitydelta.org/research-notes/robust-growth-pipeline-progress-and-cash-position/